Effect of granulocyte colony-stimulating factor treatment on ex vivo neutrophil functions in nonneutropenic surgical intensive care patients

被引:19
作者
Gerber, A
Struy, H
Weiss, G
Lippert, H
Ansorge, S
Schulz, HU
机构
[1] Univ Magdeburg, Inst Immunol, D-39120 Magdeburg, Germany
[2] Univ Magdeburg, Dept Gen Surg, D-39120 Magdeburg, Germany
关键词
D O I
10.1089/107999000750053753
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Granulocyte colony-stimulating factor (G-CSF) preferentially stimulates growth and differentiation of neutrophil precursors and activates neutrophil functions. The aim of the present study was to investigate the functional response of the neutrophil to exogenous recombinant human G-CSF (rHuG-CSF) in nonneutropenic patients. In 30 surgical intensive care unit patients with severely impaired wound healing, leukocyte differential count, plasma G-CSF level, and a broad spectrum of neutrophil functions were monitored before (day 0), throughout (days 1 and 5), and at days 1 and 5 after stopping G-CSF treatment. G-CSF application resulted in a 3.5-fold increase in peripheral blood granulocyte count at day 5 of treatment. The mean plasma G-CSF level rose from 48 to a maximum of 2314 pg/ml at day 1 of G-CSF therapy. Neutrophil chemotaxis and stimulated lysozyme release were decreased throughout G-CSF treatment, whereas respiratory burst activity, phagocytic activity, and intracellular calcium concentration were enhanced by G-CSF. Neutrophil membrane depolarization remained unaffected. The increased count and activation state of neutrophils were associated with clinical improvement in most of these patients. Thus, G-CSF may be a useful adjuvant treatment for nonneutropenic patients with severely impaired wound healing.
引用
收藏
页码:1083 / 1090
页数:8
相关论文
共 31 条
[1]   In vivo effects of recombinant human granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers [J].
Allen, RC ;
Stevens, PR ;
Price, TH ;
Chatta, GS ;
Dale, DC .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) :1184-1192
[2]  
Cebon J, 1994, Curr Opin Hematol, V1, P228
[3]   Infections in nonleukopenic compromised hosts (diabetes mellitus, SLE, steroids, and asplenia) in critical care [J].
Cunha, BA .
CRITICAL CARE CLINICS, 1998, 14 (02) :263-+
[4]   GRANULOCYTE-COLONY-STIMULATING FACTOR - ROLE AND RELATIONSHIPS IN INFECTIOUS-DISEASES [J].
DALE, DC ;
LILES, WC ;
SUMMER, WR ;
NELSON, S .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (04) :1061-1075
[5]   Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia [J].
deBoisblanc, BP ;
Mason, CM ;
Andresen, J ;
Logan, E ;
Bear, MB ;
Johnson, S ;
Shellito, J ;
Summer, WR ;
Nelson, S .
RESPIRATORY MEDICINE, 1997, 91 (07) :387-394
[6]   Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection [J].
Gough, A ;
Clapperton, M ;
Rolando, N ;
Foster, AVM ;
PhilpottHoward, J ;
Edmonds, ME .
LANCET, 1997, 350 (9081) :855-859
[7]   Safety of a low dosage filgrastim (rhG-CSF) treatment in non neutropenic surgical intensive care patients with an inflammatory process [J].
GrossWeege, W ;
Weiss, M ;
Schneider, M ;
Wenning, M ;
Harms, B ;
Dumon, K ;
Ohmann, C ;
Roher, HD .
INTENSIVE CARE MEDICINE, 1997, 23 (01) :16-22
[8]  
GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
[9]   Role of granulocyte colony-stimulating factor in infection and inflammation [J].
Hartung, T ;
von Aulock, S ;
Wendel, A .
MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 1998, 187 (02) :61-69
[10]   EFFECT OF GRANULOCYTE-COLONY-STIMULATING FACTOR TREATMENT ON EX-VIVO BLOOD CYTOKINE RESPONSE IN HUMAN VOLUNTEERS [J].
HARTUNG, T ;
DOCKE, WD ;
GANTNER, F ;
KRIEGER, G ;
SAUER, A ;
STEVENS, P ;
VOLK, HD ;
WENDEL, A .
BLOOD, 1995, 85 (09) :2482-2489